This one has news coming out tonight so much so that you'll have to call in the order to buy shares you can't buy them through online buy's only by calling it in!
"The World Vaccine Congress Lyon 2007 is a international forum where leading researchers with breakthrough technologies get to present their work and learn from each other," says Rothman about the 3 day-long conference that is to include interactive panels and high-level case studies. "I am pleased that Advaxis is included among the distinguished group of leaders in this space."
Dr. Rothman is expected to discuss the advantages of Listeria bacterial vector systems in evoking a safe and effective therapeutic immune response and will include information on the pre-clinical data demonstrating how this technology induces anti-tumor immunity. Rothman is expected to discuss Phase I/II study data relating to both the safety of the current live cervical cancer vaccine as well as the use of this agent as an efficacious therapy.
In April, Advaxis completed the enrollment and dosing in patients diagnosed with advanced, recurrent, or progressive cervical cancer in its Phase I/II clinical trial of Lovaxin C. Assessments made by an independent safety panel prior to beginning each higher dosage group found that Lovaxin C, a modified Listeria-based live vaccine is safe, even in very ill end-stage cancer patients.